Henry Schein (HSIC) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
12 May, 2026Voting matters and shareholder proposals
Board recommends voting FOR director nominees William K. Daniel and Max Lin, citing their independence and qualifications.
Board recommends voting AGAINST Proposal 4, a shareholder proposal to govern by majority vote, submitted by John Chevedden.
Shareholders are encouraged to review the full text of Proposal 4 and the company's opposition statement in the proxy statement.
Board of directors and corporate governance
William K. Daniel and Max Lin were added to the board as part of a strategic partnership with KKR, which invested $250 million and is the largest stockholder.
Both nominees meet all Nasdaq and SEC independence standards and serve on key committees.
Mr. Daniel contributed to CEO compensation design; Mr. Lin participated in the CEO search and evaluation process.
Executive compensation and say-on-pay
Mr. Daniel's experience includes overseeing executive compensation at Danaher Corporation, informing his role in designing compensation for the incoming CEO.
Latest events from Henry Schein
- Global leader in dental and medical products with $13.2B sales and strong growth momentum.HSIC
Corporate presentation - Q2 2026 saw strong sales, margin, and EPS growth, prompting a raised FY2026 outlook.HSIC
Q2 2026 - Strategic initiatives and value creation projects drive stable growth and operational efficiency.HSIC
Baird Global Healthcare Conference 2025 - Transformation, innovation, and disciplined growth drive strong outlook and value creation.HSIC
Stifel Jaws & Paws Conference 2026 - Leadership changes, all proposals passed, and majority voting adopted for future governance.HSIC
AGM 2026 - Strong Q1 growth, margin expansion, and strategic focus position the company for 2026 targets.HSIC
Bank of America Global Healthcare Conference 2026 - Record Q3 2025 results, raised guidance, and $200M+ value creation initiatives announced.HSIC
Q3 2025 - Q2 2024 sales up 1.1% to $3.14B; net income and EPS declined, and guidance was reduced.HSIC
Q2 2024 - Q4 2024 non-GAAP EPS rose 80% on 5.8% sales growth; 2025 outlook targets steady gains.HSIC
Q4 2024